Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N
AUTL.OQ - Autolus Therapeutics PLC
Autolus Therapeutics PLC at TD Cowen Healthcare Conference
Mar 03, 2026 / 04:10PM GMT
=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
All right. Welcome, everybody.
Thank you for joining, at the back end of the corner of the conference. So I really appreciate you find your way. I'm Christian I. I'm the CEO of all of us, and You see, yes. This is just our disclaimers. Please look at our SEC filings for the risk factors.
We are, a, at a, very interesting point with a company which just launched our first product, which is called a CASL. It's a CD-19 CAR T product that we have an approval for acute leukemia patients. This is, these are the relapsed refractory population and in fact the adult population in that space. We had a very successful 1st year. We had the 75 million in revenue, in the 1st year of launch. We achieved market
Trustpilot
